Thanks in part to an investment from Canada’s Strategic Innovation Fund (SIF), Eurofins CDMO is building a new biologics manufacturing facility at its site in Mississauga, Ontario, just outside of Toronto.
Seven weeks after the government announced that it would contribute $22.4 million to support the $64.1 million project, Eurofins has filled in the blanks, saying that it is set to kick off construction of the site. The plant will produce monoclonal antibodies and protein therapies for clinical and commercial clients and is set for completion in April 2026, the company said in a release.
The 50,000-square-foot facility will be housed within Eurofins’ new, 14-acre campus in the Sheridan Research Park. In January of this year, Eurofins kicked off operations at its 112,000-square-foot active pharmaceutical ingredient (API) laboratories. Its operations were moved from a site in the same neighborhood.
“The facility will bolster Canada’s biomanufacturing capabilities and preparedness for future pandemics, while strengthening the biologics ecosystem and employment base in Canada,” Eurofins said in a release.
The new site will employ single-use technology. It can run in both fed-batch and perfusion modes, Eurofins said. Its fill line will have a capacity of 24.9 million units per year, it added. The government said that the investment will create 120 jobs.
Eurofins called the new site a “pivotal step,” allowing it to bring its development and manufacturing services “under one roof,” it said.
“This integrated approach facilitates efficient product development and manufacturing, particularly for complex modalities such as antibody-drug conjugates,” Eurofins added.
The parent company—which is best known for its worldwide network of laboratories which provide testing and support services to the pharmaceutical, food, environmental and other industries—acquired Ontario-based Alphora Research and France-based Amatsigroup SAS in 2017 to support its drug development platform.
In 2019, the company established Eurofins CDMO to provide drug substance and drug product manufacturing services for biologics and small molecules.